AstraZeneca to Discontinue Epanova Trial Following Disappointing Data

Date : 01/13/2020 @ 7:37AM
Source : Dow Jones News
Stock : AstraZeneca PLC (AZN)
Quote : 48.94  -0.37 (-0.75%) @ 1:00AM
After Hours
Last Trade
Last $ 48.94 ◊ 0.00 (0.00%)

AstraZeneca to Discontinue Epanova Trial Following Disappointing Data

Astrazeneca (LSE:AZN)
Historical Stock Chart

2 Months : From Dec 2019 to Feb 2020

Click Here for more Astrazeneca Charts.
   By Adriano Marchese 

AstraZeneca PLC (AZN.LN) said Monday that it will discontinue the trial for the drug Epanova following a recommendation from an independent data-monitoring committee.

The company said it has decided to close the phase three trial for the drug due to its low likelihood of demonstrating a benefit to patients with mixed dyslipidaemia who are at risk of cardiovascular disease.

"We are disappointed by these results, but we remain committed to addressing the needs of patients in the cardiovascular space where we have an extensive pipeline," Executive Vice President of BioPharmaceuticals R&D Mene Pangalos said.


Write to Adriano Marchese at


(END) Dow Jones Newswires

January 13, 2020 02:22 ET (07:22 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Latest AZN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.